Namritha Ravinder on Muck Rack

Namritha Ravinder

As seen in: Cell & Gene Therapy Insights
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Namritha

Contact Namritha, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Developing streamlined, flexible cell therapy process workflows: from upstream to formulation and fill‑finish operations

|
By Namritha Ravinder, Carl Dargitz
| Cell & Gene Therapy Insights Verified
Cell and Gene Therapy Insights 2026; 12(4), 492–501 10.18609/cgti.2026.056 Cell therapy manufacturing is evolving beyond manual open workflows, demanding closed, automated, and modular solutions to achieve scalability, consistency, and regulatory compliance.
Open in Who Shared Issue with article?

Developing streamlined, flexible cell therapy process workflows: from upstream to formulation and fill-finish operations

|
By Namritha Ravinder
| Cell & Gene Therapy Insights Verified
Recent advances in engineered cell therapy are creating demand for flexible, closed, and automated systems that can adapt to both autologous and allogeneic workflows while helping ensure consistency and GMP compliance.
Open in Who Shared Issue with article?

Toward clinical-scale nonviral gene-edited CAR-NK cells for cell therapy

|
By Namritha Ravinder, Krishanu Saha
| Cell & Gene Therapy Insights Verified
Cell & Gene Therapy Insights 2025; 11(1), 69–84 DOI: 10.18609/cgti.2024.009 Improving the accessibility and effectiveness of cell therapies is essential to meet the growing demand for cancer treatments. Engineered natural killer (NK) cells represent a promising modality, offering safety, effectiveness, and the possibility of allogeneic use.
Open in Who Shared Issue with article?
See all 4 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified